CA2434682A1 - Combinations of peroxisome proliferator-activated receptor (ppar) activator(s) and sterol absorption inhibitor(s) and treatments for vascular indications - Google Patents
Combinations of peroxisome proliferator-activated receptor (ppar) activator(s) and sterol absorption inhibitor(s) and treatments for vascular indications Download PDFInfo
- Publication number
- CA2434682A1 CA2434682A1 CA002434682A CA2434682A CA2434682A1 CA 2434682 A1 CA2434682 A1 CA 2434682A1 CA 002434682 A CA002434682 A CA 002434682A CA 2434682 A CA2434682 A CA 2434682A CA 2434682 A1 CA2434682 A1 CA 2434682A1
- Authority
- CA
- Canada
- Prior art keywords
- activated receptor
- peroxisome proliferator
- activator
- absorption inhibitor
- combinations
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/02—Halogenated hydrocarbons
- A61K31/025—Halogenated hydrocarbons carbocyclic
- A61K31/03—Halogenated hydrocarbons carbocyclic aromatic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
- A61K31/055—Phenols the aromatic ring being substituted by halogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Abstract
The present invention provides compositions, therapeutic combinations and methods including: (a) at least one peroxisome proliferator-activated receptor activator; and (b) at least one substituted azetidinone or substituted b-lactam sterol absorption inhibitor which can be useful for treating vascular conditions, diabetes, obesity and lowering plasma levels of sterols.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA2562982A CA2562982C (en) | 2001-01-26 | 2002-01-25 | Combinations of peroxisome proliferator-activated receptor (ppar) activator(s) and sterol absorption inhibitor(s) and treatments for vascular indications |
CA002563051A CA2563051A1 (en) | 2001-01-26 | 2002-01-25 | Combinations of peroxisome proliferator-activated receptor (ppar) activator(s) and sterol absorption inhibitor(s) and treatments for vascular indications |
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US26439601P | 2001-01-26 | 2001-01-26 | |
US60/264,396 | 2001-01-26 | ||
US32383901P | 2001-09-21 | 2001-09-21 | |
US60/323,839 | 2001-09-21 | ||
PCT/US2002/002009 WO2002058732A2 (en) | 2001-01-26 | 2002-01-25 | Combinations of peroxisome proliferator-activated receptor (ppar) activator(s) and sterol absorption inhibitor(s) and treatments for vascular indications |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002563051A Division CA2563051A1 (en) | 2001-01-26 | 2002-01-25 | Combinations of peroxisome proliferator-activated receptor (ppar) activator(s) and sterol absorption inhibitor(s) and treatments for vascular indications |
CA2562982A Division CA2562982C (en) | 2001-01-26 | 2002-01-25 | Combinations of peroxisome proliferator-activated receptor (ppar) activator(s) and sterol absorption inhibitor(s) and treatments for vascular indications |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2434682A1 true CA2434682A1 (en) | 2002-08-01 |
CA2434682C CA2434682C (en) | 2008-11-18 |
Family
ID=26950511
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA2562982A Expired - Fee Related CA2562982C (en) | 2001-01-26 | 2002-01-25 | Combinations of peroxisome proliferator-activated receptor (ppar) activator(s) and sterol absorption inhibitor(s) and treatments for vascular indications |
CA002434682A Expired - Lifetime CA2434682C (en) | 2001-01-26 | 2002-01-25 | Combinations of peroxisome proliferator-activated receptor (ppar) activator(s) and sterol absorption inhibitor(s) and treatments for vascular indications |
CA002563051A Abandoned CA2563051A1 (en) | 2001-01-26 | 2002-01-25 | Combinations of peroxisome proliferator-activated receptor (ppar) activator(s) and sterol absorption inhibitor(s) and treatments for vascular indications |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA2562982A Expired - Fee Related CA2562982C (en) | 2001-01-26 | 2002-01-25 | Combinations of peroxisome proliferator-activated receptor (ppar) activator(s) and sterol absorption inhibitor(s) and treatments for vascular indications |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002563051A Abandoned CA2563051A1 (en) | 2001-01-26 | 2002-01-25 | Combinations of peroxisome proliferator-activated receptor (ppar) activator(s) and sterol absorption inhibitor(s) and treatments for vascular indications |
Country Status (33)
Country | Link |
---|---|
US (5) | US20020151536A1 (en) |
EP (2) | EP1413331B1 (en) |
JP (4) | JP4777602B2 (en) |
KR (1) | KR100596257B1 (en) |
CN (1) | CN100509058C (en) |
AR (2) | AR033855A1 (en) |
AT (2) | ATE374641T1 (en) |
AU (1) | AU2002247019C1 (en) |
BR (1) | BR0206654A (en) |
CA (3) | CA2562982C (en) |
CL (1) | CL2004001174A1 (en) |
CY (2) | CY1108000T1 (en) |
CZ (2) | CZ301871B6 (en) |
DE (2) | DE60216890T2 (en) |
DK (2) | DK1353696T3 (en) |
EC (1) | ECSP11004702A (en) |
ES (2) | ES2290562T3 (en) |
HK (2) | HK1056696A1 (en) |
HU (2) | HUP0303915A3 (en) |
IL (3) | IL156445A0 (en) |
ME (1) | MEP27808A (en) |
MX (1) | MXPA03006725A (en) |
NO (1) | NO331512B1 (en) |
NZ (1) | NZ525921A (en) |
PL (1) | PL208110B1 (en) |
PT (2) | PT1413331E (en) |
RS (2) | RS51449B (en) |
RU (1) | RU2356550C2 (en) |
SI (2) | SI1353696T1 (en) |
SK (2) | SK288217B6 (en) |
TW (1) | TWI337083B (en) |
WO (1) | WO2002058732A2 (en) |
ZA (1) | ZA200305693B (en) |
Families Citing this family (50)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2004517916A (en) * | 2001-01-26 | 2004-06-17 | シェーリング コーポレイション | Combination of nicotinic acid and its derivatives and sterol absorption inhibitors, and treatment of vascular indications |
AU2002241956A1 (en) * | 2001-01-26 | 2002-08-06 | Schering Corporation | Combinations of bile acid sequestrant(s) and sterol absorption inhibitor(s) and treatments for vascular indications |
ATE345793T1 (en) * | 2001-09-21 | 2006-12-15 | Schering Corp | TREATMENT OF XANTHOMA USING AZETIDINONE DERIVATIVES AS STEROL ABSORPTION INHIBITORS |
WO2003026573A2 (en) * | 2001-09-24 | 2003-04-03 | Merck & Co., Inc. | Screening and selection methods for statin drug combinations |
GB0215579D0 (en) | 2002-07-05 | 2002-08-14 | Astrazeneca Ab | Chemical compounds |
US7135556B2 (en) * | 2002-07-19 | 2006-11-14 | Schering Corporation | NPC1L1 (NPC3) and methods of use thereof |
AR040588A1 (en) | 2002-07-26 | 2005-04-13 | Schering Corp | PHARMACEUTICAL FORMULATION INCLUDING AN INHIBITOR OF CHOLESTEROL ABSORPTION AND AN INHIBITOR OF A HMGCO TO REDUCTASE |
NZ569868A (en) * | 2002-09-27 | 2010-01-29 | Martek Biosciences Corp | Prophylactic docosahexaenoic acid therapy for patients with subclinical inflammation |
JP4633469B2 (en) * | 2002-12-16 | 2011-02-16 | キッセイ薬品工業株式会社 | Oral solid medicine |
WO2004069193A2 (en) * | 2003-02-03 | 2004-08-19 | Thomas Jefferson University | Methods and compositions for inhibiting cholesterol uptake |
US7208486B2 (en) | 2003-03-07 | 2007-04-24 | Schering Corporation | Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof |
US7235543B2 (en) | 2003-03-07 | 2007-06-26 | Schering Corporation | Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof |
JP2005015434A (en) * | 2003-06-27 | 2005-01-20 | Kotobuki Seiyaku Kk | Serum cholesterol-lowering agent or prophylactic or therapeutic agent for atherosclerosis |
JP2007510659A (en) * | 2003-11-05 | 2007-04-26 | シェーリング コーポレイション | Combinations of lipid modulators and substituted azetidinones and treatment of vascular conditions |
ATE428411T1 (en) * | 2003-11-07 | 2009-05-15 | Jj Pharma Inc | HDL-BOOSTING COMBINATION THERAPY COMPLEXES |
ATE485267T1 (en) | 2003-12-23 | 2010-11-15 | Astrazeneca Ab | DIPHENYLAZETIDINONE DERIVATIVES WITH CHOLESTERINE ABSORPTION INHIBITING EFFECT |
EP1723414A4 (en) * | 2004-01-16 | 2008-03-26 | Merck & Co Inc | Npc1l1 (npc3) and methods of identifying ligands thereof |
US20070116645A1 (en) * | 2004-02-03 | 2007-05-24 | Steven Farber | Methods and compositions for inhibiting cholesterol uptake |
US7803838B2 (en) * | 2004-06-04 | 2010-09-28 | Forest Laboratories Holdings Limited | Compositions comprising nebivolol |
CA2568640C (en) | 2004-06-04 | 2011-08-09 | Teva Pharmaceutical Industries Ltd. | Pharmaceutical composition containing irbesartan |
US7838552B2 (en) | 2004-06-04 | 2010-11-23 | Forest Laboratories Holdings Limited | Compositions comprising nebivolol |
CN1759834B (en) * | 2004-09-17 | 2010-06-23 | 中国医学科学院医药生物技术研究所 | Application of berberine or associated with Simvastatin in preparing product for preventing or curing disease or symptom related to blood fat |
US7524831B2 (en) * | 2005-03-02 | 2009-04-28 | Schering Corporation | Treatments for Flaviviridae virus infection |
UY29607A1 (en) | 2005-06-20 | 2007-01-31 | Astrazeneca Ab | CHEMICAL COMPOUNDS |
MY148538A (en) | 2005-06-22 | 2013-04-30 | Astrazeneca Ab | Novel 2-azetidinone derivatives as cholesterol absorption inhibitors for the treatment of hyperlipidaemic conditions |
SA06270191B1 (en) | 2005-06-22 | 2010-03-29 | استرازينيكا ايه بي | Novel 2-Azetidinone Derivatives as Cholesterol Absorption Inhibitors for the Treatment of Hyperlipidaemic Conditions |
EP1741427A1 (en) * | 2005-07-06 | 2007-01-10 | KRKA, D.D., Novo Mesto | Pharmaceutical composition comprising simvastatin and ezetimibe |
EP1919468A4 (en) * | 2005-07-18 | 2010-02-10 | Reliant Pharmaceuticals Inc | Treatment with azetidinone-based cholesterol absorption inhibitors and omega-3 fatty acids and a combination product thereof |
US7910698B2 (en) | 2006-02-24 | 2011-03-22 | Schering Corporation | NPC1L1 orthologues |
TW200811098A (en) | 2006-04-27 | 2008-03-01 | Astrazeneca Ab | Chemical compounds |
US20070275052A1 (en) * | 2006-05-24 | 2007-11-29 | Glenmark Pharmaceuticals Limited | Pharmaceutical compositions containing sterol inhibitors |
WO2007150063A2 (en) * | 2006-06-23 | 2007-12-27 | Cargill Incorporated | Compositions for lowering blood serum cholesterol and use in foods, beverages, and health supplements |
US20080033019A1 (en) * | 2006-08-07 | 2008-02-07 | Duke University | Cholesterol lowering drug combination |
US20080085315A1 (en) * | 2006-10-10 | 2008-04-10 | John Alfred Doney | Amorphous ezetimibe and the production thereof |
DK2167069T3 (en) * | 2007-05-23 | 2011-11-21 | Amcol International Corp | Cholesterol-interacting layered phyllosilicates and methods for reducing hypercholesterolemia in a mammal |
WO2009074286A2 (en) | 2007-12-10 | 2009-06-18 | Ratiopharm Gmbh | Pharmaceutical formulation comprising ezetimibe |
EP2168573A1 (en) * | 2008-09-30 | 2010-03-31 | LEK Pharmaceuticals D.D. | Formulations comprising ezetimibe |
CN102333528B (en) * | 2009-01-26 | 2013-12-18 | 台北医学大学 | Use of pterosin compounds for treating diabetes and obesity |
PL2229938T3 (en) | 2009-03-13 | 2012-09-28 | Sanovel Ilac Sanayi Ve Ticaret As | Ezetimibe compositions |
US9388440B2 (en) | 2009-04-01 | 2016-07-12 | Mylan Laboratories Limited | Enzymatic process for the preparation of (S)-5-(4-fluoro-phenyl)-5-hydroxy-1morpholin-4-yl-pentan-1-one, an intermediate of Ezetimibe and further conversion to Ezetimibe |
TR200904500A2 (en) | 2009-06-10 | 2009-10-21 | Öner Levent | Methods and pharmaceutical formulations for the preparation of ezetimibe nanocrystals. |
KR102098032B1 (en) | 2012-09-27 | 2020-04-07 | 교와 가부시키가이샤 | Therapeutic agent for dyslipidemia |
KR20150079373A (en) | 2013-12-30 | 2015-07-08 | 한미약품 주식회사 | Composite formulation for oral administration comprising ezetimibe and rosuvastatin |
CN104337785A (en) * | 2014-11-04 | 2015-02-11 | 万全万特制药江苏有限公司 | Orally disintegrating tablet containing ezetimibe and preparation method of orally disintegrating tablet |
CN105213340A (en) * | 2015-10-29 | 2016-01-06 | 无锡福祈制药有限公司 | A kind of Ezetimibe sheet and preparation method thereof |
JP2017210455A (en) * | 2016-05-27 | 2017-11-30 | ニプロ株式会社 | Ezetimibe-containing pharmaceutical composition |
CN106310173A (en) * | 2016-08-24 | 2017-01-11 | 厦门三川利生物科技有限公司 | Multi-vitamin acidity alcohol containing peroxisome proliferator activated receptor and preparing method thereof |
EP3437636A1 (en) | 2017-08-02 | 2019-02-06 | Adamed sp. z o.o. | Pharmaceutical composition comprising ezetimibe |
CN109718215A (en) * | 2017-10-30 | 2019-05-07 | 海南皇隆制药股份有限公司 | A kind of Ezetimibe piece |
KR101983298B1 (en) * | 2018-06-11 | 2019-05-29 | 연세대학교 산학협력단 | Pharmaceutical coomposition for preventing or treating inflammasome mediated inflammatory disease |
Family Cites Families (174)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2809194A (en) * | 1957-10-08 | Thiadiazine type natriuretic agents | ||
US3108097A (en) * | 1963-10-22 | Ehnojs | ||
US1286A (en) * | 1839-08-13 | Richard else | ||
NL108640C (en) * | 1958-05-07 | |||
NL127065C (en) * | 1964-04-22 | |||
NL137318C (en) * | 1964-06-09 | |||
FI52570C (en) * | 1969-04-16 | 1977-10-10 | Sumitomo Chemical Co | Process for producing the cholesterol or lipoid content of the blood using phenoxyaliphatic carboxylic acid compounds and ester compounds. |
US3692895A (en) * | 1970-09-08 | 1972-09-19 | Norman A Nelson | Method of reducing hypercholesteremia in humans employing a copolymer of polyethylenepolyamine and a bifunctional substance, such as epichlorohydria |
DE2230383C3 (en) * | 1971-10-01 | 1981-12-03 | Boehringer Mannheim Gmbh, 6800 Mannheim | Phenoxyalkylcarboxylic acid derivatives and processes for making the same |
US4148923A (en) * | 1972-05-31 | 1979-04-10 | Synthelabo | 1-(3'-Trifluoromethylthiophenyl)-2-ethylaminopropane pharmaceutical composition and method for treating obesity |
US3948973A (en) * | 1972-08-29 | 1976-04-06 | Sterling Drug Inc. | Halocyclopropyl substituted phenoxyalkanoic acids |
US4626549A (en) * | 1974-01-10 | 1986-12-02 | Eli Lilly And Company | Treatment of obesity with aryloxyphenylpropylamines |
US4179515A (en) * | 1975-02-12 | 1979-12-18 | Orchimed S. A. | Benzoylphenoxy propionic acid, esters thereof and pharmaceutical composition |
JPS5195049A (en) * | 1975-02-12 | 1976-08-20 | * **********so*****no***tsu*****************************************ni*no | |
US4235896A (en) * | 1975-02-12 | 1980-11-25 | Orchimed S.A. | Benzyl-phenoxy acid esters and hyperlipaemia compositions containing the same |
US4075000A (en) * | 1975-05-27 | 1978-02-21 | Eli Lilly And Company | Herbicidal use of 4-amino-3,3-dimethyl-1-phenyl-2-azetidinones |
US4304718A (en) * | 1975-10-06 | 1981-12-08 | Fujisawa Pharmaceutical Co., Ltd. | 2-Azetidinone compounds and processes for preparation thereof |
US4576753A (en) * | 1975-10-06 | 1986-03-18 | Fujisawa Pharmaceutical Co., Ltd. | Azetidinone compounds and processes for preparation thereof |
US4472309A (en) * | 1975-10-06 | 1984-09-18 | Fujisawa Pharmaceutical Co., Ltd. | 2-Azetidinone compounds and processes for preparation thereof |
US4166907A (en) * | 1976-11-01 | 1979-09-04 | E. R. Squibb & Sons, Inc. | 3,3-Dichloro-2-azetidinone derivatives having antiinflammatory activity |
US4144232A (en) * | 1976-12-23 | 1979-03-13 | Eli Lilly And Company | Substituted azetidin-2-one antibiotics |
FR2403078A1 (en) * | 1977-09-19 | 1979-04-13 | Lafon Labor | NEW PROCESS FOR THE PREPARATION OF PHARMACEUTICAL, COSMETIC OR DIAGNOSIS FORMS |
IT1157365B (en) * | 1977-10-24 | 1987-02-11 | Sandoz Ag | MEDICATIONS TO TREAT OBESITY OR REDUCE BODY WEIGHT |
US4250191A (en) * | 1978-11-30 | 1981-02-10 | Edwards K David | Preventing renal failure |
US4375475A (en) * | 1979-08-17 | 1983-03-01 | Merck & Co., Inc. | Substituted pyranone inhibitors of cholesterol synthesis |
US4260743A (en) * | 1979-12-31 | 1981-04-07 | Gist-Brocades N.V. | Preparation of β-lactams and intermediates therefor |
US4444784A (en) * | 1980-08-05 | 1984-04-24 | Merck & Co., Inc. | Antihypercholesterolemic compounds |
DE3107100A1 (en) * | 1981-02-20 | 1982-09-09 | Schering Ag, 1000 Berlin Und 4619 Bergkamen | AZAPROSTACYCLINE, METHOD FOR THEIR PRODUCTION AND THEIR PHARMACEUTICAL USE |
US4500456A (en) * | 1981-03-09 | 1985-02-19 | Eli Lilly And Company | Preparation of 4-fluoroazetidinones using FClO3 |
US4784734A (en) * | 1981-04-10 | 1988-11-15 | Otsuka Kagaku Yakuhin Kabushiki Kaisha | Azetidinone derivatives and process for the preparation of the same |
US4602005A (en) * | 1982-05-17 | 1986-07-22 | Medical Research Foundation Of Oregon | Tigogenin cellobioside for treating hypercholesterolemia and atherosclerosis |
US4602003A (en) * | 1982-05-17 | 1986-07-22 | Medical Research Foundation Of Oregon | Synthetic compounds to inhibit intestinal absorption of cholesterol in the treatment of hypercholesterolemia |
US4443372A (en) * | 1982-06-23 | 1984-04-17 | Chevron Research Company | 1-Alkyl derivatives of 3-aryloxy-4-(2-carbalkoxy)-phenyl-azet-2-ones as plant growth regulators |
US4534786A (en) * | 1982-06-23 | 1985-08-13 | Chevron Research Company | 1-Alkyl derivatives of 3-aryloxy-4-(2-carbalkoxy)-phenyl-azet-2-ones as plant growth regulators |
US4595532A (en) * | 1983-02-02 | 1986-06-17 | University Of Notre Dame Du Lac | N-(substituted-methyl)-azetidin-2-ones |
CA1256650A (en) * | 1983-03-25 | 1989-06-27 | Toshinari Tamura | Process of producing 2-azetidinone-4-substituted compounds, and medicaments containing the compounds |
US4614614A (en) * | 1983-03-28 | 1986-09-30 | Ciba-Geigy Corporation | Process for the manufacture of optically active azetidinones |
US4675399A (en) * | 1983-03-28 | 1987-06-23 | Notre Dame University | Cyclization process for β-lactams |
WO1985004876A1 (en) * | 1984-04-24 | 1985-11-07 | Takeda Chemical Industries, Ltd. | 2-azetidinone derivatives and process for their preparation |
US4576749A (en) * | 1983-10-03 | 1986-03-18 | E. R. Squibb & Sons, Inc. | 3-Acylamino-1-carboxymethylaminocarbonyl-2-azetidinones |
US5229381A (en) * | 1983-12-01 | 1993-07-20 | Merck & Co., Inc. | Substituted azetidinones as anti-inflammatory and antidegenerative agents |
US4680391A (en) * | 1983-12-01 | 1987-07-14 | Merck & Co., Inc. | Substituted azetidinones as anti-inflammatory and antidegenerative agents |
US5229510A (en) * | 1983-12-01 | 1993-07-20 | Merck & Co., Inc. | β-lactams useful in determining the amount of elastase in a clinical sample |
US4654362A (en) * | 1983-12-05 | 1987-03-31 | Janssen Pharmaceutica, N.V. | Derivatives of 2,2'-iminobisethanol |
FR2561916B1 (en) * | 1984-03-30 | 1987-12-11 | Lafon Labor | GALENIC FORM FOR ORAL ADMINISTRATION AND METHOD FOR PREPARING IT BY LYOPHILIZATION OF AN OIL-TO-WATER EMISSION |
US4633017A (en) * | 1984-08-03 | 1986-12-30 | E. R. Squibb & Sons, Inc. | N-hydroxy protecting groups and process for the preparation of 3-acylamino-1-hydroxy-2-azetidinones |
US4581170A (en) * | 1984-08-03 | 1986-04-08 | E. R. Squibb & Sons, Inc. | N-hydroxyl protecting groups and process and intermediates for the preparation of 3-acylamino-1-hydroxy-2-azetidinones |
US4576748A (en) * | 1984-09-17 | 1986-03-18 | Merck & Co., Inc. | 3-Hydroxy-3-aminoethyl β-lactams |
US4620867A (en) * | 1984-09-28 | 1986-11-04 | Chevron Research Company | 1-carbalkoxyalkyl-3-aryloxy-4-(substituted-2'-carboxyphenyl)-azet-2-ones as plant growth regulators and herbicides |
AR240698A1 (en) * | 1985-01-19 | 1990-09-28 | Takeda Chemical Industries Ltd | Process for the preparation of 5-(4-(2-(5-ethyl-2-pyridil)-ethoxy)benzyl)-2,4-thiazolodinedione and their salts |
US4642903A (en) * | 1985-03-26 | 1987-02-17 | R. P. Scherer Corporation | Freeze-dried foam dosage form |
US4680289A (en) * | 1985-06-05 | 1987-07-14 | Progenics, Inc. | Treatment of obesity and diabetes using sapogenins |
EP0234484B1 (en) * | 1986-02-19 | 1993-10-20 | Sanraku Incorporated | Novel azetidinone derivatives |
GB8607312D0 (en) * | 1986-03-25 | 1986-04-30 | Ici Plc | Therapeutic agents |
FR2598146B1 (en) * | 1986-04-30 | 1989-01-20 | Rech Ind | NEW PROCESS FOR THE PREPARATION OF FIBRATES. |
DE3621861A1 (en) * | 1986-06-30 | 1988-01-14 | Laszlo Dr Med Ilg | USE OF ARYLOXYCARBONIC ACID DERIVATIVES AGAINST DERMATOLOGICAL DISEASES |
FR2602423B1 (en) * | 1986-08-08 | 1989-05-05 | Ethypharm Sa | PROCESS FOR THE PREPARATION OF A FENOFIBRATE-BASED MEDICINAL PRODUCT, OBTAINED BY THIS PROCESS |
US4814354A (en) * | 1986-09-26 | 1989-03-21 | Warner-Lambert Company | Lipid regulating agents |
US4803266A (en) * | 1986-10-17 | 1989-02-07 | Taisho Pharmaceutical Co., Ltd. | 3-Oxoalkylidene-2-azetidinone derivatives |
US5229362A (en) * | 1986-12-15 | 1993-07-20 | Eli Lilly And Company | Antibiotic A10255 complex and factors, and process and production therefor |
PH25145A (en) * | 1986-12-15 | 1991-02-19 | Laverne Dwaine Boeck | Process for producing the a10255 complex and corresponding microorganism |
JPS63156788A (en) * | 1986-12-22 | 1988-06-29 | Sanraku Inc | Optically active azetidinones |
US5110730A (en) * | 1987-03-31 | 1992-05-05 | The Scripps Research Institute | Human tissue factor related DNA segments |
DE3877406T2 (en) * | 1987-04-28 | 1993-06-09 | Fujisawa Astra Ltd | BENZOTHIAZOLINONE DERIVATIVES, THEIR PRODUCTION AND PHARMACEUTICAL COMPOSITION. |
US5106833A (en) * | 1987-07-23 | 1992-04-21 | Washington University | Coagulation inhibitors |
US5091525A (en) * | 1987-10-07 | 1992-02-25 | Eli Lilly And Company | Monohydrate and DMF solvates of a new carbacephem antibiotic |
US4834846A (en) * | 1987-12-07 | 1989-05-30 | Merck & Co., Inc. | Process for deblocking N-substituted β-lactams |
US5385885A (en) * | 1988-01-15 | 1995-01-31 | Gasic; Gregory P. | Inhibition of smooth muscle cell proliferation by antistasin and tick anticoagulant peptide |
FR2627696B1 (en) * | 1988-02-26 | 1991-09-13 | Fournier Innovation Synergie | NEW GALENIC FORM OF FENOFIBRATE |
DE3807895A1 (en) * | 1988-03-10 | 1989-09-21 | Knoll Ag | PRODUCTS CONTAINING A CALCIUM ANTAGONIST AND A LIPID DOWNER |
GB8813012D0 (en) * | 1988-06-02 | 1988-07-06 | Norsk Hydro As | Non-b-oxidizable fatty acid analogues to reduce concentration of cholesterol & triglycerides in blood of mammals |
FR2634376B1 (en) * | 1988-07-21 | 1992-04-17 | Farmalyoc | NOVEL SOLID AND POROUS UNIT FORM COMPRISING MICROPARTICLES AND / OR NANOPARTICLES, AS WELL AS ITS PREPARATION |
US4952689A (en) * | 1988-10-20 | 1990-08-28 | Taisho Pharmaceutical Co., Ltd. | 3-(substituted propylidene)-2-azetidinone derivates for blood platelet aggregation |
CA1340977C (en) * | 1988-11-15 | 2000-04-25 | Monty Krieger | Scavenger receptor protein and antibody thereto |
US5112616A (en) * | 1988-11-30 | 1992-05-12 | Schering Corporation | Fast dissolving buccal tablet |
US5073374A (en) * | 1988-11-30 | 1991-12-17 | Schering Corporation | Fast dissolving buccal tablet |
US4876365A (en) * | 1988-12-05 | 1989-10-24 | Schering Corporation | Intermediate compounds for preparing penems and carbapenems |
US5260305A (en) * | 1988-12-12 | 1993-11-09 | E. R. Squibb & Sons, Inc. | Combination of pravastatin and nicotinic acid or related acid and method for lowering serum cholesterol using such combination |
FR2640621B1 (en) * | 1988-12-19 | 1992-10-30 | Centre Nat Rech Scient | N-ARYL-AZETIDINONES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS ELASTASE INHIBITORS |
US4990535A (en) * | 1989-05-03 | 1991-02-05 | Schering Corporation | Pharmaceutical composition comprising loratadine, ibuprofen and pseudoephedrine |
CA2016467A1 (en) | 1989-06-05 | 1990-12-05 | Martin Eisman | Method for treating peripheral atherosclerotic disease employing an hmg coa reductase inhibitor and/or a squalene synthetase inhibitor |
JPH03108490A (en) * | 1989-06-30 | 1991-05-08 | Shionogi & Co Ltd | Phospholipase a2 inhibitor |
US5021461A (en) * | 1989-07-26 | 1991-06-04 | Merrell Dow Pharmaceuticals Inc. | Method of treating diabetes mellitus with bisphenol derivatives |
US4983597A (en) * | 1989-08-31 | 1991-01-08 | Merck & Co., Inc. | Beta-lactams as anticholesterolemic agents |
US5219574A (en) * | 1989-09-15 | 1993-06-15 | Cima Labs. Inc. | Magnesium carbonate and oil tableting aid and flavoring additive |
US5223264A (en) * | 1989-10-02 | 1993-06-29 | Cima Labs, Inc. | Pediatric effervescent dosage form |
US5178878A (en) * | 1989-10-02 | 1993-01-12 | Cima Labs, Inc. | Effervescent dosage form with microparticles |
US5188825A (en) * | 1989-12-28 | 1993-02-23 | Iles Martin C | Freeze-dried dosage forms and methods for preparing the same |
US5298497A (en) * | 1990-05-15 | 1994-03-29 | E. R. Squibb & Sons, Inc. | Method for preventing onset of hypertension employing a cholesterol lowering drug |
US5622985A (en) * | 1990-06-11 | 1997-04-22 | Bristol-Myers Squibb Company | Method for preventing a second heart attack employing an HMG CoA reductase inhibitor |
US5120729A (en) * | 1990-06-20 | 1992-06-09 | Merck & Co., Inc. | Beta-lactams as antihypercholesterolemics |
US5120713A (en) * | 1990-09-10 | 1992-06-09 | Applied Research Systems Ars Holding N.V. | Treatment of obesity with an alpha-2-adrenergic agonist and a growth hormone releasing peptide |
US5190970A (en) * | 1990-10-19 | 1993-03-02 | E. R. Squibb & Sons, Inc. | Method for preventing onset of or treating Type II diabetes employing a cholesterol lowering drug alone or in combination with an ace inhibitor |
US5130333A (en) * | 1990-10-19 | 1992-07-14 | E. R. Squibb & Sons, Inc. | Method for treating type II diabetes employing a cholesterol lowering drug |
JP2640986B2 (en) * | 1990-11-08 | 1997-08-13 | 高砂香料工業株式会社 | Process for producing (1'R, 3S) -3- (1'-hydroxyethyl) -azetidin-2-one or a derivative thereof |
IL100091A (en) * | 1990-12-12 | 1998-08-16 | Zeneca Ltd | Pharmaceutical compositions containing a physical form of n-[4-[5-(cyclopentyloxycarbonyl)amino-1-methyl indol-3-yl-methyl]-2-methylbenzenesulpho-namide and process for their preparation |
US5145684A (en) * | 1991-01-25 | 1992-09-08 | Sterling Drug Inc. | Surface modified drug nanoparticles |
AU642066B2 (en) | 1991-01-25 | 1993-10-07 | Nanosystems L.L.C. | X-ray contrast compositions useful in medical imaging |
US5399363A (en) * | 1991-01-25 | 1995-03-21 | Eastman Kodak Company | Surface modified anticancer nanoparticles |
US5157025A (en) * | 1991-04-01 | 1992-10-20 | E. R. Squibb & Sons, Inc. | Method for lowering serum cholesterol employing a phosphorus containing ace inhibitor alone or in combination with a cholesterol lowering drug |
DE69222532T2 (en) | 1991-07-23 | 1998-02-26 | Schering Corp | SUBSTITUTED BETA LACTAM COMPOUNDS AS HYPOCHOLESTEROLEMIC AGENTS AND METHOD FOR THE PRODUCTION THEREOF |
US5162117A (en) * | 1991-11-22 | 1992-11-10 | Schering Corporation | Controlled release flutamide composition |
US5278176A (en) * | 1992-08-21 | 1994-01-11 | Abbott Laboratories | Nicotine derivatives that enhance cognitive function |
NZ248813A (en) * | 1992-11-25 | 1995-06-27 | Eastman Kodak Co | Polymeric grinding media used in grinding pharmaceutical substances |
US5503846A (en) * | 1993-03-17 | 1996-04-02 | Cima Labs, Inc. | Base coated acid particles and effervescent formulation incorporating same |
US5412092A (en) * | 1993-04-23 | 1995-05-02 | Bristol-Myers Squibb Company | N-substituted 2-azetidinones |
ATE205475T1 (en) * | 1993-07-09 | 2001-09-15 | Schering Corp | METHOD FOR PRODUCING AZETIDINONES |
WO1995001782A2 (en) * | 1993-07-09 | 1995-01-19 | R.P. Scherer Corporation | Method for making freeze dried drug dosage forms |
US5622719A (en) * | 1993-09-10 | 1997-04-22 | Fuisz Technologies Ltd. | Process and apparatus for making rapidly dissolving dosage units and product therefrom |
US5631365A (en) * | 1993-09-21 | 1997-05-20 | Schering Corporation | Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents |
US5595761A (en) * | 1994-01-27 | 1997-01-21 | The Board Of Regents Of The University Of Oklahoma | Particulate support matrix for making a rapidly dissolving tablet |
US5627176A (en) * | 1994-03-25 | 1997-05-06 | Schering Corporation | Substituted azetidinone compounds useful as hypocholesterolemic agents |
US5718388A (en) * | 1994-05-25 | 1998-02-17 | Eastman Kodak | Continuous method of grinding pharmaceutical substances |
TW384224B (en) * | 1994-05-25 | 2000-03-11 | Nano Sys Llc | Method of preparing submicron particles of a therapeutic or diagnostic agent |
WO1995035277A1 (en) * | 1994-06-20 | 1995-12-28 | Schering Corporation | Substituted azetidinone compounds useful as hypocholesterolemic agents |
US5633246A (en) * | 1994-11-18 | 1997-05-27 | Schering Corporation | Sulfur-substituted azetidinone compounds useful as hypocholesterolemic agents |
US5624920A (en) * | 1994-11-18 | 1997-04-29 | Schering Corporation | Sulfur-substituted azetidinone compounds useful as hypocholesterolemic agents |
FR2730231B1 (en) * | 1995-02-02 | 1997-04-04 | Fournier Sca Lab | COMBINATION OF FENOFIBRATE AND VITAMIN E, USE IN THERAPEUTICS |
US5639475A (en) * | 1995-02-03 | 1997-06-17 | Eurand America, Incorporated | Effervescent microcapsules |
US5518738A (en) * | 1995-02-09 | 1996-05-21 | Nanosystem L.L.C. | Nanoparticulate nsaid compositions |
US5591456A (en) * | 1995-02-10 | 1997-01-07 | Nanosystems L.L.C. | Milled naproxen with hydroxypropyl cellulose as a dispersion stabilizer |
US5510118A (en) * | 1995-02-14 | 1996-04-23 | Nanosystems Llc | Process for preparing therapeutic compositions containing nanoparticles |
JP3144624B2 (en) * | 1995-06-02 | 2001-03-12 | 杏林製薬株式会社 | N-benzyldioxothiazolidylbenzamide derivative and method for producing the same |
US5612378A (en) * | 1995-06-06 | 1997-03-18 | 3-Dimensional Pharmaceuticals, Inc. | Bis-arylsulfonylaminobenzamide derivatives and the use thereof as factor Xa inhibitors |
US5612353A (en) * | 1995-06-07 | 1997-03-18 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Substituted (sulfinic acid, sulfonic acid, sulfonylamino or sulfinylamino) N-[(aminoiminomethyl)phenylalkyl]-azaheterocyclylamide compounds |
US5607697A (en) * | 1995-06-07 | 1997-03-04 | Cima Labs, Incorporated | Taste masking microparticles for oral dosage forms |
FR2738817B1 (en) * | 1995-09-14 | 1997-10-17 | Adir | NOVEL SUBSTITUTED ALKANOIC 2,2-DIMETHYL-OMEGA-PHENOXY ACIDS AND ESTERS, THEIR PREPARATION PROCESS AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM |
US5618707A (en) * | 1996-01-04 | 1997-04-08 | Schering Corporation | Stereoselective microbial reduction of 5-fluorophenyl-5-oxo-pentanoic acid and a phenyloxazolidinone condensation product thereof |
WO1997016424A1 (en) * | 1995-11-02 | 1997-05-09 | Schering Corporation | Process for preparing 1-(4-fluorophenyl)-3(r)-(3(s)-hydroxy-3-([phenyl or 4-fluorophenyl])-propyl)-4(s)-(4-hydroxyphenyl)-2-azetidinone |
GB9600464D0 (en) * | 1996-01-09 | 1996-03-13 | Smithkline Beecham Plc | Novel method |
US5859051A (en) * | 1996-02-02 | 1999-01-12 | Merck & Co., Inc. | Antidiabetic agents |
GB9606805D0 (en) * | 1996-03-30 | 1996-06-05 | Glaxo Wellcome Inc | Medicaments |
EP0904082A4 (en) * | 1996-04-17 | 2001-09-26 | Merck & Co Inc | Combination therapy for reducing the risks associated with cardiovascular disease |
US5858409A (en) * | 1996-04-17 | 1999-01-12 | Fmc Corporation | Hydrolyzed cellulose granulations for pharmaceuticals |
IL126979A (en) * | 1996-05-24 | 2000-10-31 | Schering Corp | Antifungal composition with enhanced bioavailability |
US5739321A (en) * | 1996-05-31 | 1998-04-14 | Schering Corporation | 3-hydroxy γ-lactone based enantionselective synthesis of azetidinones |
US5886171A (en) * | 1996-05-31 | 1999-03-23 | Schering Corporation | 3-hydroxy gamma-lactone based enantioselective synthesis of azetidinones |
CA2229077C (en) * | 1996-06-12 | 2007-09-25 | Kyowa Hakko Kogyo Co., Ltd. | Lipid metabolism improving agent |
US5883109A (en) * | 1996-07-24 | 1999-03-16 | Bristol-Myers Squibb Company | Method for lowering serum lipid levels employing an MTP inhibitor in combination with another cholesterol lowering drug |
FR2761266B1 (en) * | 1997-03-28 | 1999-07-02 | Sanofi Sa | PHARMACEUTICAL COMPOSITION FORMED BY WET GRANULATION FOR THE ORAL ADMINISTRATION OF A DERIVATIVE OF N-PIPERIDINO-3- PYRAZOLECARBOXAMIDE, ITS SALTS AND THEIR SOLVATES |
ATE530180T1 (en) * | 1997-04-02 | 2011-11-15 | Brigham & Womens Hospital | METHOD FOR DETERMINING THE INDIVIDUAL RISK PROFILES OF ATHEROSCLEROTIC DISEASES |
ES2125198B1 (en) * | 1997-05-13 | 1999-11-16 | Vita Invest Sa | FIXED-DOSE ASSOCIATION OF AN ANGIOTENSIN CONVERTING ENZYME INHIBITOR AND AN ANTAGONIST OF THE CALCIUM CHANNELS, PROCEDURE FOR ITS PREPARATION AND USE FOR THE TREATMENT OF CARDIOVASCULAR DISEASES. |
US5886191A (en) * | 1997-08-18 | 1999-03-23 | Dupont Pharmaceuticals Company | Amidinoindoles, amidinoazoles, and analogs thereof |
US5869098A (en) * | 1997-08-20 | 1999-02-09 | Fuisz Technologies Ltd. | Fast-dissolving comestible units formed under high-speed/high-pressure conditions |
AR016827A1 (en) * | 1997-08-22 | 2001-08-01 | Smithkline Beecham Corp | PROCEDURE FOR THE PREPARATION OF A PHARMACEUTICAL TABLET |
US6180660B1 (en) * | 1997-08-26 | 2001-01-30 | Merck & Co., Inc. | Cholesterol-lowering therapy |
AU9309898A (en) * | 1997-09-09 | 1999-03-29 | Du Pont Pharmaceuticals Company | Benzimidazolinones, benzoxazolinones, benzopiperazinones, indanones, and derivatives thereof as inhibitors of factor xa |
US20030153541A1 (en) * | 1997-10-31 | 2003-08-14 | Robert Dudley | Novel anticholesterol compositions and method for using same |
US6027747A (en) * | 1997-11-11 | 2000-02-22 | Terracol; Didier | Process for the production of dry pharmaceutical forms and the thus obtained pharmaceutical compositions |
US6008237A (en) * | 1997-12-19 | 1999-12-28 | Merck & Co., Inc. | Arylthiazolidinedione derivatives |
US6180625B1 (en) * | 1998-03-24 | 2001-01-30 | Novo Nordisk A/S | Heterocyclic compounds regulating clotting |
CA2321538A1 (en) * | 1998-03-27 | 1999-10-07 | Dupont Pharmaceuticals Company | Disubstituted pyrazolines and triazolines as factor xa inhibitors |
EP1073643B1 (en) * | 1998-04-23 | 2004-12-29 | Dr. Reddy's Laboratories Ltd. | New heterocyclic compounds and their use in medicine, process for their preparation and pharmaceutical compositions containing them |
US6207822B1 (en) * | 1998-12-07 | 2001-03-27 | Schering Corporation | Process for the synthesis of azetidinones |
JP2002533411A (en) * | 1998-12-23 | 2002-10-08 | ジー.ディー.サール エルエルシー | Combinations for applying to cardiovascular |
US6180138B1 (en) * | 1999-01-29 | 2001-01-30 | Abbott Laboratories | Process for preparing solid formulations of lipid-regulating agents with enhanced dissolution and absorption |
US6033656A (en) * | 1999-05-04 | 2000-03-07 | Sumitomo Chemical Company, Limited | Method of preventing or alleviating mammalian obesity |
US6207699B1 (en) * | 1999-06-18 | 2001-03-27 | Richard Brian Rothman | Pharmaceutical combinations for treating obesity and food craving |
US6174665B1 (en) * | 1999-09-10 | 2001-01-16 | Biex, Inc. | Hormone replacement therapy monitoring |
AU1756201A (en) * | 1999-12-08 | 2001-06-18 | Pharmacia Corporation | Nanoparticulate eplerenone compositions |
US6191117B1 (en) * | 2000-07-10 | 2001-02-20 | Walter E. Kozachuk | Methods of producing weight loss and treatment of obesity |
US20020132855A1 (en) * | 2000-08-03 | 2002-09-19 | Nelson Edward B. | Use of acetaminophen to prevent and treat arteriosclerosis |
DE10042447A1 (en) * | 2000-08-29 | 2002-03-28 | Aventis Pharma Gmbh | Vertebrate intestinal protein that absorbs cholesterol and use of this protein to identify inhibitors of intestinal cholesterol transport |
CA2423141A1 (en) * | 2000-09-27 | 2002-04-04 | Merck & Co., Inc. | Benzopyrancarboxylic acid derivatives for the treatment of diabetes and lipid disorders |
MXPA03005019A (en) * | 2000-12-21 | 2003-09-25 | Avantis Pharma Deutschland Gmb | Diphenyl azetidinone derivatives, method for the production thereof, medicaments containing these compounds, and their use. |
IL156550A0 (en) * | 2000-12-21 | 2004-01-04 | Aventis Pharma Gmbh | Novel 1,2-diphenzylazetidinones, method for producing the same, medicaments containing said compounds, and the use thereof for treating disorders of the lipid metabolism |
IL156552A0 (en) * | 2000-12-21 | 2004-01-04 | Aventis Pharma Gmbh | Diphenyl azetidinone derivatives, method for the production thereof, medicaments containing these compounds, and their use |
AU2002241956A1 (en) * | 2001-01-26 | 2002-08-06 | Schering Corporation | Combinations of bile acid sequestrant(s) and sterol absorption inhibitor(s) and treatments for vascular indications |
BR0206644A (en) * | 2001-01-26 | 2004-02-25 | Schering Corp | Sterol absorption inhibitor (s) combinations with cardiovascular agent (s) for the treatment of vascular conditions |
CA2437118A1 (en) * | 2001-02-09 | 2002-08-22 | Merck & Co., Inc. | 2-aryloxy-2-arylalkanoic acids for diabetes and lipid disorders |
WO2002072104A2 (en) * | 2001-03-08 | 2002-09-19 | Merck & Co., Inc. | Antihypertensive agent and cholesterol absorption inhibitor combination therapy |
US7348334B2 (en) * | 2001-04-09 | 2008-03-25 | Dr. Reddy's Laboratories Limited | Monocyclic derivatives of aryl alkanoic acids and their use in medicine: process for their preparation and pharmaceutical compositions containing them |
WO2002081454A1 (en) * | 2001-04-09 | 2002-10-17 | Dr. Reddy's Laboratories Ltd. | Derivatives of aryl acids, their use in medicine, process for their preparation and pharmaceutical compositions containing them |
AU2002308778A1 (en) * | 2001-05-25 | 2002-12-09 | Schering Corporation | Use of azetidinone substituted derivatives in the treatment of alzheimer's disease |
-
2002
- 2002-01-25 PT PT04000161T patent/PT1413331E/en unknown
- 2002-01-25 CA CA2562982A patent/CA2562982C/en not_active Expired - Fee Related
- 2002-01-25 JP JP2002559066A patent/JP4777602B2/en not_active Expired - Lifetime
- 2002-01-25 EP EP04000161A patent/EP1413331B1/en not_active Expired - Lifetime
- 2002-01-25 EP EP02714773A patent/EP1353696B1/en not_active Expired - Lifetime
- 2002-01-25 DE DE60216890T patent/DE60216890T2/en not_active Expired - Lifetime
- 2002-01-25 SK SK50001-2012A patent/SK288217B6/en not_active IP Right Cessation
- 2002-01-25 AR ARP020100269A patent/AR033855A1/en not_active Application Discontinuation
- 2002-01-25 RS YUP-586/03A patent/RS51449B/en unknown
- 2002-01-25 AT AT04000161T patent/ATE374641T1/en active
- 2002-01-25 MX MXPA03006725A patent/MXPA03006725A/en active IP Right Grant
- 2002-01-25 ES ES04000161T patent/ES2290562T3/en not_active Expired - Lifetime
- 2002-01-25 AT AT02714773T patent/ATE348649T1/en active
- 2002-01-25 RU RU2003126184/15A patent/RU2356550C2/en active
- 2002-01-25 SI SI200230471T patent/SI1353696T1/en unknown
- 2002-01-25 PL PL368653A patent/PL208110B1/en unknown
- 2002-01-25 NZ NZ525921A patent/NZ525921A/en not_active IP Right Cessation
- 2002-01-25 KR KR1020037009749A patent/KR100596257B1/en active IP Right Review Request
- 2002-01-25 DE DE60222773T patent/DE60222773T2/en not_active Expired - Lifetime
- 2002-01-25 AU AU2002247019A patent/AU2002247019C1/en active Active
- 2002-01-25 WO PCT/US2002/002009 patent/WO2002058732A2/en active Application Filing
- 2002-01-25 IL IL15644502A patent/IL156445A0/en unknown
- 2002-01-25 CA CA002434682A patent/CA2434682C/en not_active Expired - Lifetime
- 2002-01-25 BR BR0206654-8A patent/BR0206654A/en not_active Application Discontinuation
- 2002-01-25 ME MEP-278/08A patent/MEP27808A/en unknown
- 2002-01-25 HU HU0303915A patent/HUP0303915A3/en not_active Application Discontinuation
- 2002-01-25 DK DK02714773T patent/DK1353696T3/en active
- 2002-01-25 SK SK948-2003A patent/SK287988B6/en not_active IP Right Cessation
- 2002-01-25 PT PT02714773T patent/PT1353696E/en unknown
- 2002-01-25 US US10/057,323 patent/US20020151536A1/en not_active Abandoned
- 2002-01-25 CA CA002563051A patent/CA2563051A1/en not_active Abandoned
- 2002-01-25 DK DK04000161T patent/DK1413331T3/en active
- 2002-01-25 CZ CZ20032030A patent/CZ301871B6/en not_active IP Right Cessation
- 2002-01-25 HU HU1500186A patent/HU230253B1/en unknown
- 2002-01-25 RS RSP-2010/0015A patent/RS20100015A/en unknown
- 2002-01-25 TW TW091101264A patent/TWI337083B/en not_active IP Right Cessation
- 2002-01-25 CN CNB028072081A patent/CN100509058C/en not_active Expired - Lifetime
- 2002-01-25 SI SI200230630T patent/SI1413331T1/en unknown
- 2002-01-25 CZ CZ2010307A patent/CZ309209B6/en not_active IP Right Cessation
- 2002-01-25 ES ES02714773T patent/ES2274013T3/en not_active Expired - Lifetime
- 2002-05-01 US US10/136,968 patent/US7030106B2/en not_active Expired - Lifetime
-
2003
- 2003-06-15 IL IL156445A patent/IL156445A/en unknown
- 2003-07-23 ZA ZA2003/05693A patent/ZA200305693B/en unknown
- 2003-07-25 NO NO20033355A patent/NO331512B1/en not_active IP Right Cessation
- 2003-12-18 HK HK03109220A patent/HK1056696A1/en not_active IP Right Cessation
- 2003-12-18 HK HK04106306A patent/HK1063607A1/en not_active IP Right Cessation
-
2004
- 2004-05-20 CL CL200401174A patent/CL2004001174A1/en unknown
- 2004-11-29 US US10/998,400 patent/US7612058B2/en active Active
-
2005
- 2005-06-22 US US11/158,429 patent/US20060199793A1/en not_active Abandoned
-
2007
- 2007-02-20 CY CY20071100238T patent/CY1108000T1/en unknown
- 2007-05-28 JP JP2007141163A patent/JP4937836B2/en not_active Expired - Lifetime
- 2007-08-29 US US11/897,227 patent/US20080058306A1/en not_active Abandoned
- 2007-11-12 JP JP2007293724A patent/JP2008088184A/en active Pending
- 2007-11-28 AR ARP070105283A patent/AR064012A2/en unknown
- 2007-12-03 CY CY20071101535T patent/CY1107045T1/en unknown
-
2008
- 2008-05-13 IL IL191417A patent/IL191417A/en active IP Right Grant
-
2011
- 2011-02-09 EC EC2011004702A patent/ECSP11004702A/en unknown
-
2012
- 2012-01-31 JP JP2012018544A patent/JP2012087149A/en not_active Withdrawn
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2434682A1 (en) | Combinations of peroxisome proliferator-activated receptor (ppar) activator(s) and sterol absorption inhibitor(s) and treatments for vascular indications | |
WO2002058731A3 (en) | Combinations of sterol absorption inhibitor(s) with cardiovascular agent(s) for the treatment of vascular conditions | |
WO2002058733A3 (en) | Combinations of bile acid sequestrant(s) and sterol absorption inhibitor(s) and treatments for vascular indications | |
WO2005046797A3 (en) | Combinations of lipid modulating agents and substituted azetidinones and treatments for vascular conditions | |
WO2002058734A3 (en) | Combinations of sterol absorption inhibitor(s) with blood modifier(s) for treating vascular conditions | |
WO2002058685A3 (en) | Combinations of nicotinic acid and derivatives thereof and sterol absorption inhibitor(s) and treatments for vascular indications | |
MXPA05009501A (en) | Substituted azetidinone compounds, formulations and uses thereof for the treatment of hypercholeterolemia. | |
MY138838A (en) | A pharmaceutical composition comprising a combination of valsartan, amlodipine and hydrochlorothiazide | |
WO2002058696A3 (en) | The use of substituted azetidinone compounds for the treatment of sitosterolemia | |
WO2002098350A3 (en) | Pyranoindazoles and their use for the treatment of glaucoma | |
WO2003026643A3 (en) | Treatment of xanthoma with azetidinone derivatives as sterol absorption inhibitors | |
HK1064950A1 (en) | Methods for treating or preventing vascular inflammation using sterol absorption inhibitor(s) | |
WO2002050090A8 (en) | Sugar-substituted 2-azetidinones useful as hypocholesterolemic agents | |
MXPA05009503A (en) | Substituted azetidinone compounds, formulations and uses thereof for the treatment of hypercholesterolemia. | |
MY141528A (en) | Anilinopyrazole derivatives useful for the treatment of diabetes | |
AU2003263760A1 (en) | Methods for the treatment or prevention of obesity | |
WO2004024066A3 (en) | Method of treating diabetes and related conditions | |
WO2004019874A3 (en) | Substituted 5-chroman-5-yl-ethylamine compounds and their use for the treatment of glaucoma | |
EP1864680A3 (en) | Combinations of peroxisome proliferator-activated receptor (PPAR) activator(s) and sterol absorption inhibitor(s) and treatments for vascular indications | |
WO2003101379A3 (en) | Pyranoindazoles and their use for the treatment of glaucoma | |
EP1859796A3 (en) | Treatment of xanthoma with azetidinone derivatives as sterol absorption inhibitors | |
NO20033401L (en) | Chemical connections | |
NO20053517D0 (en) | Use of lipid-lowering agents | |
ECSP034702A (en) | COMBINATIONS DEACTIVATOR (S) OF THE RECEIVER OF PEROXISMAL PROLIFERATION ACTIVATION (PPAR) AND INHIBITOR (ES) OF STEROL ABSORPTION AND TREATMENT FOR VASCULAR INDICATIONS | |
AU2003282171A1 (en) | Method for diagnosing rhabdomyosarcoma and pharmaceutical compositions for the treatment and/or prevention of rhabdomyosarcoma |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
MKEX | Expiry |
Effective date: 20220125 |